quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·3d
PRRelease
Cogent Biosciences Inc. logo

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

COGT· Cogent Biosciences Inc.
Health Care
Original source

Companies

  • COGT
    Cogent Biosciences Inc.
    Health Care

Recent analyst ratings

  • Mar 16UpdateJefferies-
  • Nov 10UpdateStifel$40.00
  • Nov 10UpdateWedbush$38.00
  • Oct 16UpdateStifel$16.00
  • Sep 3UpdateRaymond James$30.00
  • Mar 7UpdateScotiabank$17.00

Related

  • SEC18h
    SEC Form DEFA14A filed by Cogent Biosciences Inc.
  • SEC18h
    SEC Form DEF 14A filed by Cogent Biosciences Inc.
  • PR7d
    Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
  • INSIDER20d
    SEC Form 4 filed by Ferrante Karen Jean
  • PR23d
    Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
  • INSIDER23d
    SEC Form 4 filed by Fairmount Funds Management Llc
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.
  • ANALYST39d
    Jefferies resumed coverage on Cogent Biosciences
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022